You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CLINICAL TRIALS PROFILE FOR LISINOPRIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lisinopril

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000542 ↗ Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-08-01 To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
NCT00004266 ↗ Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes Completed Hennepin County Medical Center, Minneapolis Phase 3 1993-08-01 OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00004266 ↗ Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1993-08-01 OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lisinopril

Condition Name

Condition Name for Lisinopril
Intervention Trials
Hypertension 45
Healthy 6
Cardiovascular Disease 6
Diabetic Nephropathy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lisinopril
Intervention Trials
Hypertension 49
Kidney Diseases 17
Cardiovascular Diseases 10
Diabetes Mellitus 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lisinopril

Trials by Country

Trials by Country for Lisinopril
Location Trials
United States 436
Canada 8
Puerto Rico 6
Spain 6
Switzerland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lisinopril
Location Trials
Texas 24
Ohio 21
California 21
New York 20
Minnesota 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lisinopril

Clinical Trial Phase

Clinical Trial Phase for Lisinopril
Clinical Trial Phase Trials
Phase 4 31
Phase 3 24
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lisinopril
Clinical Trial Phase Trials
Completed 82
Recruiting 12
Terminated 12
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lisinopril

Sponsor Name

Sponsor Name for Lisinopril
Sponsor Trials
GlaxoSmithKline 14
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 9
Novartis 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lisinopril
Sponsor Trials
Other 130
Industry 63
NIH 22
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Lisinopril: Clinical Trials, Market Analysis, and Projections

Introduction to Lisinopril

Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely prescribed for the treatment of hypertension, heart failure, and certain kidney conditions related to diabetes. It works by relaxing blood vessels, reducing blood pressure, and improving blood flow. Here, we will delve into recent clinical trials, market analysis, and future projections for lisinopril.

Clinical Trials Update

PARADISE-MI Trial

While the PARADISE-MI trial focused on sacubitril/valsartan rather than lisinopril, it provides context on the broader landscape of cardiovascular treatments. However, to directly address lisinopril, we look at other studies.

Lisinopril vs Other Antihypertensives

A notable study is the ALLHAT trial, which compared outcomes in hypertensive patients treated with lisinopril, chlorthalidone, or amlodipine. The trial found that while lisinopril was effective, there were significant differences in outcomes based on race. For example, black patients experienced a greater reduction in blood pressure with chlorthalidone compared to lisinopril, highlighting the need for personalized treatment approaches[4].

Market Analysis

Current Market Size and Growth

The global lisinopril market has seen significant growth in recent years. As of 2023, the market size was approximately $1.66 billion and is projected to grow to $1.76 billion in 2024, with a compound annual growth rate (CAGR) of 6.0%[5].

Regional Outlook

North America was the largest region in the lisinopril market in 2023, but the Asia-Pacific region is expected to be the fastest-growing during the forecast period. The market report covers various countries including the USA, Canada, Italy, Spain, Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, and the UK[5].

Market Segments

The lisinopril market is segmented by disease (hypertension, heart failure, heart attack, strokes, diabetic kidney disease), dosage (tablet, liquid), dosage strength (10mg/12.5mg, 20mg/12.5mg), brand (Zestoretic, Prinivil, Zestril), population type (children, adults), end-users (hospitals, specialty clinics, home healthcare), and distribution channels (direct tender, hospital pharmacy, retail pharmacy, online pharmacy)[3].

Market Dynamics

Drivers

  • Rising Prevalence of Hypertension and Cardiovascular Diseases: The increasing global burden of hypertension and cardiovascular diseases is a primary driver for the lisinopril market. As lifestyles become more sedentary and dietary habits less healthy, the demand for antihypertensive medications like lisinopril continues to rise[3].
  • Generic Versions and Cost-Effectiveness: The availability of generic lisinopril at more affordable prices enhances its market penetration. Generic versions offer a viable option for patients, healthcare providers, and payers, especially in regions where cost considerations are crucial[3].

Opportunities

  • Growing Awareness and Early Diagnosis: Increasing public awareness campaigns and healthcare initiatives focused on hypertension and cardiovascular diseases create opportunities for the lisinopril market. Early diagnosis and intervention expand the market as healthcare professionals prescribe lisinopril as a front-line treatment[3].
  • Combination Therapies: The exploration and development of combination therapies involving lisinopril offer a promising avenue for market growth. Combining lisinopril with other cardiovascular medications could provide synergistic effects, improve treatment efficacy, and enhance patient adherence[3].

Restraints/Challenges

  • Side Effects and Tolerability Issues: Common side effects of lisinopril, such as dizziness, headaches, and cough, can affect patient adherence and overall market growth. Managing these side effects is crucial for maintaining patient satisfaction and treatment efficacy[3].

Market Projections

Forecast Period

The global lisinopril market is expected to grow significantly over the next few years. By 2028, the market size is projected to reach $2.26 billion, with a CAGR of 6.4% during the forecast period. This growth is attributed to the rising prevalence of hypertension and cardiovascular diseases, the availability of generic versions, increased awareness and early diagnosis, and an aging population[5].

Regional Growth

Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by increasing healthcare expenditure, lifestyle changes, and expanded screening programs. North America will continue to be a major market, but the growth rate is expected to be higher in the Asia-Pacific region[5].

Key Takeaways

  • Clinical Trials: Recent trials highlight the importance of personalized treatment approaches and the effectiveness of lisinopril in various patient populations.
  • Market Growth: The lisinopril market is driven by the rising prevalence of hypertension and cardiovascular diseases, the availability of generic versions, and increased awareness and early diagnosis.
  • Regional Outlook: North America is currently the largest market, but Asia-Pacific is expected to be the fastest-growing region in the forecast period.
  • Market Segments: The market is segmented by disease, dosage, brand, population type, end-users, and distribution channels, offering various opportunities for market players.

FAQs

What is the primary use of lisinopril?

Lisinopril is primarily prescribed to treat high blood pressure (hypertension), heart failure, and certain kidney conditions related to diabetes.

What are the common side effects of lisinopril?

Common side effects of lisinopril include dizziness, headaches, and cough.

How does the lisinopril market segment by disease?

The lisinopril market is segmented by disease into hypertension, heart failure, heart attack, strokes, and diabetic kidney disease.

What is the projected market size of lisinopril by 2028?

The global lisinopril market is projected to reach $2.26 billion by 2028, with a CAGR of 6.4% during the forecast period.

Which region is expected to be the fastest-growing in the lisinopril market?

The Asia-Pacific region is expected to be the fastest-growing in the lisinopril market during the forecast period.

Sources

  1. PARADISE-MI Trial: "Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Mortality and Morbidity in Patients with Acute Myocardial Infarction" - American College of Cardiology[1].
  2. Global Lisinopril Market Research Report: Value Market Research[2].
  3. Global Lisinopril Market – Industry Trends and Forecast to 2031: Data Bridge Market Research[3].
  4. Outcomes in Hypertensive Black and Nonblack Patients Treated with Regimens Based on Valsartan or Amlodipine: JAMA Network[4].
  5. Lisinopril Global Market Report 2024: The Business Research Company[5].

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.